PolyPid Ltd. Boosts Share Offering Size to $15M
Ticker: PYPD · Form: 6-K · Filed: Nov 26, 2025 · CIK: 1611842
| Field | Detail |
|---|---|
| Company | Polypid Ltd. (PYPD) |
| Form Type | 6-K |
| Filed Date | Nov 26, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Key Dollar Amounts | $8,250,000, $15,000,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: equity-offering, capital-raise, at-the-market
TL;DR
PolyPid just doubled its ATM offering to $15M via Oppenheimer.
AI Summary
On November 26, 2025, PolyPid Ltd. announced an increase in the maximum aggregate offering price of its ordinary shares under its Sales Agreement with Oppenheimer & Co. Inc. The offering size was raised from $8,250,000 to $15,000,000. This update relates to their ongoing at-the-market equity offering program.
Why It Matters
This filing indicates PolyPid Ltd. is increasing its capital raising capacity, potentially to fund ongoing operations, research, or business development activities.
Risk Assessment
Risk Level: medium — Increasing an at-the-market offering can dilute existing shareholders and may signal a need for capital, but it also provides flexibility for fundraising.
Key Numbers
- $15.0M — New Offering Size (Increased from $8.25M under the Sales Agreement with Oppenheimer & Co. Inc.)
- $8.25M — Previous Offering Size (The initial maximum aggregate offering price before the increase.)
Key Players & Entities
- PolyPid Ltd. (company) — Registrant
- Oppenheimer & Co. Inc. (company) — Sales Agent
- $8,250,000 (dollar_amount) — Previous maximum offering price
- $15,000,000 (dollar_amount) — New maximum offering price
- November 26, 2025 (date) — Date of announcement
- November 8, 2024 (date) — Date of original Sales Agreement
FAQ
What is the purpose of increasing the offering size?
The filing does not explicitly state the purpose, but increasing the offering size under an at-the-market program typically provides flexibility for capital raising to fund operations, research, or strategic initiatives.
Who is the sales agent for this offering?
Oppenheimer & Co. Inc. is the sales agent for the Sales Agreement under which the offering is being made.
When was the original Sales Agreement established?
The original Sales Agreement with Oppenheimer & Co. Inc. was dated November 8, 2024.
What type of securities are being offered?
The offering involves PolyPid Ltd.'s ordinary shares, no par value per share.
What was the previous maximum offering price?
The previous maximum aggregate offering price was $8,250,000.
Filing Stats: 359 words · 1 min read · ~1 pages · Grade level 8.8 · Accepted 2025-11-26 16:01:05
Key Financial Figures
- $8,250,000 — Co. Inc., dated November 8, 2024, from $8,250,000 to $15,000,000. A copy of the opinion o
- $15,000,000 — ed November 8, 2024, from $8,250,000 to $15,000,000. A copy of the opinion of Sullivan & Wo
Filing Documents
- ea0267107-6k_polypid.htm (6-K) — 15KB
- ea026710701ex5-1_polypid.htm (EX-5.1) — 12KB
- ex5-1_001.jpg (GRAPHIC) — 3KB
- 0001213900-25-115470.txt ( ) — 32KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. POLYPID LTD. Date: November 26, 2025 By: /s/ Dikla Czaczkes Akselbrad Name : Dikla Czaczkes Akselbrad Title: Chief Executive Officer 3